Aviragen Therapeutics (NASDAQ:AVIR) Files An 8-K Regulation FD Disclosure

Item 7.01 and shall not be deemed to be filed for purposes of
Section 17 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed to be incorporated by
reference with any filing under the Securities Act of 1933, as
amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

About Aviragen Therapeutics (NASDAQ:AVIR)

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Aviragen Therapeutics (NASDAQ:AVIR) Recent Trading Information

Aviragen Therapeutics (NASDAQ:AVIR) closed its last trading session up +0.04 at 1.28 with 17,881 shares trading hands.